Cinepazide maleate

i.p.

2-Propen-1-one, 1-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]-3-(3, 4, 5-trimethoxyphenyl)-, (2Z)-2-butenedioate (1:1)

4 mg/kg, 20 mg/kg, 100 mg/kg and 150 mg/kg

Cinepazide (3 mg/kg -30 mg/kg, i.v.) produces a dose-related and transient increase in vertebral, carotid, renal and femoral arterial flow as well as cardiac output and a decrease in total peripheral resistance in anesthetized dogs. Cinepazide exerts positive inotropic and chronotropic actions. Cinepazide (30 mg/kg, i.v.) potentiates the vertebral vasodilator response of dogs to intravertebral adenosine and cyclic AMP. Intravertebral cinepazide (1 mg -10 mg) increases vertebral blood flow in a dose-related manner and the effect is partially inhibited by intravenous pretreatment with aminophylline but not by pretreatment with autonomic antagonists. [1] Cinepazide is well absorbed and more than 60% of the dose is excreted within 24 hours. In 5 days, rats, dogs, and man excretes in the urine and faeces respectively 36.7% and 58.3%, 33.4% and 68.6%, and 61.3% and 38.1% dose. [2] Cinepazide at doses of 1 mg/kg - 3 mg/kg i.v. decreases systemic blood pressure by 4% and reflexly increases heart rate by 8%. [3] Cinepazide selectively stimulates the functional activities of 5-HT neurons in the brain, which are depressed by hypoxia. [4]

Cinepazide maleate Chemical Structure

2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO